XML 40 R29.htm IDEA: XBRL DOCUMENT v3.5.0.2
Available-for-Sale Securities and Fair Value Measurements (Details) - USD ($)
$ in Thousands
9 Months Ended
Sep. 30, 2016
Dec. 31, 2015
Available-for-sale securities    
Amortized Cost $ 146,460 $ 176,778
Gross Unrealized Gains 8 0
Gross Unrealized Losses 0 (2)
Estimated Fair Value $ 146,468 176,776
Maturity period for marketable securities    
Maximum contractual maturity period 1 year  
Average duration 2 months  
Theravance Biopharma    
Maturity period for marketable securities    
Gain on sale $ 1,200  
Cash and cash equivalents    
Available-for-sale securities    
Estimated Fair Value 90,696 148,673
Short-term marketable securities    
Available-for-sale securities    
Estimated Fair Value 55,772 28,103
U.S. government agencies    
Available-for-sale securities    
Amortized Cost 19,913 14,406
Gross Unrealized Gains 8 0
Gross Unrealized Losses 0 (1)
Estimated Fair Value 19,921 14,405
U.S. corporate notes    
Available-for-sale securities    
Amortized Cost   2,702
Gross Unrealized Gains   0
Gross Unrealized Losses   (1)
Estimated Fair Value   2,701
U.S. commercial paper    
Available-for-sale securities    
Amortized Cost 64,838 10,997
Gross Unrealized Gains 0 0
Gross Unrealized Losses 0 0
Estimated Fair Value 64,838 10,997
Money market funds    
Available-for-sale securities    
Amortized Cost 61,709 148,673
Gross Unrealized Gains 0 0
Gross Unrealized Losses 0 0
Estimated Fair Value $ 61,709 $ 148,673